



EUROPEAN UNION OF MEDICAL SPECIALISTS (UEMS)
EUROPEAN ACCREDITATION COUNCIL FOR CME (EACCME®)

RUE DE L'INDUSTRIE 24, BE- 1040 BRUSSELS
T + 32 2 649 51 64
eaccme.uems.eu - elarning@uems.eu

Conflict of Interest Disclosure Form

(to be completed by the Medical Officer who takes responsibility for the application)

NAME: Markus Eckstein

AFFILIATION: Institute of Pathology, University

Hospital Erlangen and FAU Erlangen-Nürnberg

In accordance with criterion 18 of document UEMS 2023.08.rev "EACCME® Criteria for the Accreditation of E-Learning Materials (ELM)", all declarations of perceived or actual conflicts of interest for the last 3 years, whether due to a financial or other relationship, must be provided to the EACCME® upon submission of the application. Declarations must be made available online on the ELM page. Declarations must include whether any fee, honorarium or arrangement for re-imbursement of expenses in relation to the ELM has been provided.

DISCLOSURE

☐ I have no potential conflict of interest to report

☒ I have the following potential conflict(s) of interest to report

Type of affiliation / financial interest

Name of commercial company

Prof. Dr. Dr. Markus Eckstein has received consulting fees from Ferring, AstraZeneca, Janssen (Johnson & Johnson), Genomic Health, Diaceutics, Gilead, MSD, Merck, and Bicycle Therapeutics. He has received honoraria for lectures, presentations, and educational activities from AstraZeneca, Roche, Janssen (Johnson & Johnson), Owkin, Diaceutics, Ferring, Eisai, Merck, Bicycle Therapeutics, and Zytomed Systems. He has received payments for expert testimony from AstraZeneca, Janssen (Johnson & Johnson), Astellas, Genomic Health, Diaceutics, Gilead, MSD, Merck, and Bicycle Therapeutics. He has received travel support from AstraZeneca, Roche, MSD, Janssen (Johnson & Johnson), Diaceutics,

Astellas, Ferring, Eisai, Merck, and Bicycle Therapeutics. He serves on the Clinical Advisory Board of Bicycle Therapeutics and on the boards of the BRIDGE Consortium, the European Society of Uro pathology (ESUP) of the European Association of Urology (EAU), and the International Society of Urological Pathology (ISUP) of the European Association of Urology (EAU). He has also received equipment, materials, or other services including research funding from STRATIFYER, Janssen (Johnson & Johnson), AstraZeneca/MedImmune, Owkin, Gilead, and Bicycle Therapeutics, BMS, QUiP GmbH. He declares stock ownership of BicycleTx and MSD Shares.

Prof. Dr. Dr. Markus Eckstein has received consulting fees from Ferring, AstraZeneca, Janssen (Johnson & Johnson), Genomic Health, Diaceutics, Gilead, MSD, Merck, and Bicycle Therapeutics. He has received honoraria for lectures, presentations, and educational activities from AstraZeneca, Roche, Janssen (Johnson & Johnson), Owkin, Diaceutics, Ferring, Eisai, Merck, Bicycle Therapeutics, and Zytomed Systems. He has received payments for expert testimony from AstraZeneca, Janssen (Johnson & Johnson), Astellas, Genomic Health, Diaceutics, Gilead, MSD, Merck, and Bicycle Therapeutics. He has received travel support from AstraZeneca, Roche, MSD, Janssen (Johnson & Johnson), Diaceutics, Astellas, Ferring, Eisai, Merck, and Bicycle Therapeutics. He serves on the Clinical Advisory Board of Bicycle Therapeutics and on the boards of the BRIDGE Consortium, the European Society of Uro pathology (ESUP) of the European Association of Urology (EAU), and the International Society of Urological Pathology (ISUP) of the European Association of Urology (EAU). He has also received equipment, materials, or other services including research funding from STRATIFYER, Janssen (Johnson & Johnson), AstraZeneca/MedImmune, Owkin, Gilead, and Bicycle Therapeutics, BMS, QUiP GmbH. He declares stock ownership of BicycleTx and MSD Shares.

Spouse/partner: None

Other support (please specify): None

Signature: M. Eckstein

Date: 04.09.2026
